Cyclin A immunohistochemistery in Wilms tumor | ||||
| Fayoum University Medical Journal | ||||
| Volume 13, Issue 1, January 2024, Page 52-61 PDF (323.55 K) | ||||
| Document Type: Review Articles | ||||
| DOI: 10.21608/fumj.2023.233338.1254 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Norhan Osama Mohamed   1; Hala Elhanbouli2; Alaa Saad3; Mahmoud Elzimbily4
| ||||
| 1Pathology department, Faculty of medicine, Fayoum University, Fayoum, Egypt | ||||
| 2Pathology Department. Faculty of medicine, Fayoum University, Fayoum, Egypt | ||||
| 3Pathology department, Faculty of medicine Fayoum University, Fayoum, Egypt | ||||
| 4Pediatric Oncology and Stem cell transplantation, South Egypt Cancer institute, Assuit UNIVERSITY, Assuit, Egypt | ||||
| Abstract | ||||
| Introduction: In human malignancies, cyclin A worse prognosis relates to an overexpression. We examined the relationships between cyclin A immunohistochemistry expression and the clinicopathological features of Wilms tumor (WT), preoperative chemotherapy (PrOpChTh), overall survival (OS), and other factors. Aim of the study: The objective of this study is to determine the prognosis of Wilms tumor (WT) patients utilizing immunohistochemistry (IHC) of cyclin A. Subjects and Methods: WT patients who had nephrectomy surgery at a tertiary referral hospital between January 1996 and December 2015 were included in the retrospective study and non-concurrent cohort analysis. Over the 5-year follow-up period, recurrence, and cancer-specific mortality (CSM) were identified as adverse outcomes. The cyclin A IHC procedure employed formalin-fixed, paraffin-embedded WT tissues. Results: Patients with WTs had 33.4 percent greater cyclin A levels. Blastemal components were much more overexpressed in stage 3 and stage 4 cancers (77.8 percent and 66.7 percent , respectively). Cyclin A was discovered to be overexpressed in 66.7 percent of metastasizing patients but only 33.3 percent of non-metastasizing patients. High recurrence rates were also connected to CSM and cyclin A immunopositivity. Risk factors such as advanced stage, UFH, extracapsular extension, tumour rupture, lymphadenopathy, and venous thrombosis were not associated with a poor prognosis. Patients who have had recurrences have a worse likelihood of survival. Conclusions: Overexpression of Cyclin A in WT may indicate a bad prognosis. More patients should be included in future study. WT's capacity to spread metastatically was unaffected by cyclin A overexpression. | ||||
| Keywords | ||||
| Nephroblastoma; Prognosis; Immunohistochemical markers | ||||
|
Statistics Article View: 21 PDF Download: 16 |
||||
